Month: January 2025

“Alcohol Use Disorder Treatment Market”

(Albany, USA) DelveInsight’s Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, emerging alcohol use disorder drugs, market share of individual therapies, and current and forecasted alcohol use disorder market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

 The Alcohol Use Disorder market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Key Takeaways from the Alcohol Use Disorder Market Report

• According to DelveInsight’s analysis, the market size of alcohol use disorder in the 7MM was USD 620 million in 2023.
• As per DelveInsight analysis, the 12-month diagnosed prevalent cases of AUD in the 7MM were found to be approximately 25 million cases in 2023, which are expected to increase by 2034.
• Prominent alcohol use disorder companies working in the market, including Adial Pharmaceuticals, Corcept Therapeutics, Clearmind Medicine, Clairvoyant Therapeutics, Bioprojet, and others, are actively working on innovative alcohol use disorder drugs. These novel alcohol use disorder therapies are anticipated to enter the alcohol use disorder market in the forecast period and are expected to change the market.
• Some of the key alcohol use disorder treatments include AD04 (ondansetron), CORT 118335 (Miricorilant) (mifepristone), CMND-100, Psilocybin, BP1.3656, and others. 
• In November 2024, Adial Pharmaceuticals was granted a patent by the United States Patent and Trademark Office. The patent covers a broader range of genotype combinations identified by the company’s proprietary genetic diagnostic for targeted treatment of AUD with AD04, its lead investigational drug candidate. Additionally, in the same month, the company announced positive topline results from the pharmacokinetics (PK) study of AD04. This data will support the optimization of study design elements for the upcoming Phase 3 clinical trial of AD04.
• In August 2024, Adial Pharmaceuticals entered a collaboration with Boudicca, which will assist in developing the technical and regulatory strategies for Adial’s companion diagnostic genetic test.
• In July 2024,  Adial Pharmaceuticals submitted a new patent application for AD04, targeting the treatment of Alcohol Use Disorder. This patent is expected to protect Adial’s key assets until at least 2044 if granted. That same month, Adial Pharmaceuticals advanced to the second cohort in its pharmacokinetics study of AD04 for AUD.
• In July 2024, the US FDA approved the IND application for CMND-100 oral capsule, enabling the company to initiate a Phase I/IIa clinical trial in the US for the treatment of AUD. Additionally, Clearmind Medicine announced a strategic partnership with JS First Sdn. Bhd. to identify global manufacturers and distributors for its innovative MEAI-based alcohol substitute beverages, advancing its international expansion efforts.
• In June 2024, Adial Pharmaceuticals published the previously reported results from its Phase III ONWARD study in the European Journal of Internal Medicine.

Discover which therapies are expected to grab the alcohol use disorder market share @ Alcohol Use Disorder Market Report

Alcohol Use Disorder Overview

Alcohol use disorder (AUD) is a prevalent substance use disorder marked by excessive and uncontrollable drinking that adversely affects a person’s physical, emotional, and social well-being. It can range from mild to severe, depending on the number of symptoms an individual exhibits. Those with AUD may experience both intoxication and withdrawal symptoms, including mood instability, impaired judgment, slurred speech, difficulties with attention or memory, poor coordination, sweating, rapid heart rate, hand tremors, and seizures. 

The disorder has various underlying causes, with genetic, physiological, psychological, and social factors all influencing an individual’s behavior. Healthcare professionals utilize the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for diagnosing and assessing the severity of AUD, requiring the presence of at least two out of the 11 diagnostic criteria outlined in the DSM-V to confirm a diagnosis.

Alcohol Use Disorder Epidemiology Segmentation

The alcohol use disorder epidemiology section provides insights into the historical and current alcohol use disorder patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The alcohol use disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• 12-month Diagnosed Prevalent Cases of AUD 
• Gender-specific Diagnosed Prevalent Cases of AUD
• Type-specific Diagnosed Prevalent Cases of AUD 

Download the report to understand which factors are driving alcohol use disorder epidemiology trends @ Alcohol Use Disorder Epidemiological Insights

Alcohol Use Disorder Treatment Market 

Management strategies for patients with alcohol use disorder must be customized based on several factors, including the patient’s presenting issues, the extent and duration of alcohol use, the severity of dependence, any co-occurring substance use disorders, physical and mental health conditions, and the patient’s motivation to change. It is crucial to begin the management process by engaging the patient and understanding their initial treatment goals.

The primary aim of AUD treatment is typically either complete abstinence or a significant reduction in heavy drinking. Current treatment options include medication-assisted therapy, behavioral interventions, detoxification, and psychosocial support from rehabilitation programs and support groups. While psychosocial interventions are the cornerstone of treatment, the high rates of relapse indicate that combining pharmacotherapy with psychosocial counseling and support is the most effective approach.

At present, there are four medications approved by the US FDA for medication-assisted treatment of AUD: Acamprosate, disulfiram (ANTABUSE), oral naltrexone (REVIA), and extended-release injectable naltrexone (VIVITROL). Additionally, topiramate (TOPAMAX) is recognized by the National Institute on Alcohol Abuse and Alcoholism as a treatment option for AUD.

In Europe and Japan, nalmefene (SELINCRO) is approved and is among the first medications that can reduce alcohol cravings on an as-needed basis without necessitating abstinence. Other medications, such as baclofen (BACLOCUR) in France and sodium oxybate (SMO) in Italy, have also received approval in specific countries. Furthermore, the AUD market includes various off-label and generic products, including gabapentin, varenicline, benzodiazepines, memantine, ondansetron, aripiprazole, and suvorexant, among others.

Learn more about the market of alcohol use disorder @ Alcohol Use Disorder Treatment Market

Alcohol Use Disorder Emerging Drugs and Companies

Various therapies are being developed such as Adial Pharmaceutical’s AD04 (ondansetron), Corcept Therapeutics’ CORT118335 (miricorilant), Clearmind Medicine’s CMND-100, and others that shall further create a positive impact on the market. 

AD04 (ondansetron) is a serotonin-3 (5HT3) receptor antagonist designed to target specific genetic profiles, disrupting alcohol’s reinforcing effects and thereby reducing the urge to drink. It contains an ultra-low dose of ondansetron, commonly used as an anti-emetic for nausea following surgery or chemotherapy. AD04 also shows potential in treating other addictive behaviors such as opioid use disorder, gambling, and obesity. 

In 2024, Adial Pharmaceuticals advanced AD04 for alcohol use disorder (AUD), with the Phase III ONWARD trial showing a significant reduction in heavy drinking days within a genetically targeted subgroup. A post hoc analysis highlighted the drug’s strong efficacy in patients with certain genotypes. Additionally, the European Medicines Agency (EMA) approved Adial’s Pediatric Investigation Plan (PIP) for AD04, marking a key regulatory achievement.

CORT118335 is a glucocorticoid receptor (GR) antagonist being developed to treat alcohol use disorder. It has been shown to reduce alcohol consumption in individuals with dependence during both acute withdrawal and extended abstinence periods. However, the role of GR in regulating GABA transmission in the central amygdala (CeA) is still unclear. 

Corcept Therapeutics has completed a Phase II clinical trial of CORT118335 in patients with moderate to severe AUD, in collaboration with the Scripps Research Institute and the National Institute on Alcohol Abuse and Alcoholism. Additionally, a Phase I clinical trial for AUD treatment is underway in partnership with Johns Hopkins University.

CMND-100 is a compound based on MEAI (5-methoxy-2-aminoindane, also known as 5-MeO-AI or Chaperon) being developed for the treatment of alcohol use disorder (AUD). MEAI is a novel, psychoactive, non-hallucinogenic molecule that has been shown to reduce cravings for alcohol while providing a mild, alcohol-like euphoria. It works by interacting with the 5-HT1a and 5-HT2a serotonergic receptors. 

Clearmind Medicine recently received approval from the Israeli Ministry of Health to begin a Phase I/IIa clinical trial to evaluate MEAI in AUD patients. While the trial has demonstrated safety and efficacy in preclinical studies, it is not yet recruiting, with an expected start date in April 2024 in the US and Israel.

The other pipeline therapies for alcohol use disorder include 

• Psilocybin: Clairvoyant Therapeutics
• BP1.3656: Bioprojet

The anticipated launch of these emerging therapies are poised to transform the alcohol use disorder market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the alcohol use disorder market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about alcohol use disorder clinical trials, visit @ Alcohol Use Disorder Treatment Drugs 

Alcohol Use Disorder Market Dynamics

The alcohol use disorder market dynamics are anticipated to change in the coming years. Given the high rates of alcohol addiction and alcohol use disorder, which are contributing to increased mortality, there is a pressing need for effective treatments. This need presents opportunities for companies to introduce new therapies to the market. 

Recent advancements in understanding the neurobiological, genetic, epigenetic, psychological, social, and environmental factors critical to the etiology and treatment of AUD offer companies the chance to implement this knowledge in clinical practice and evaluate potential drugs targeting novel pathways. Ultimately, expanding patient access to pharmacotherapeutic options is essential for the AUD population.

Furthermore, many potential therapies are being investigated for the treatment of alcohol use disorder, and it is safe to predict that the treatment space will significantly impact the alcohol use disorder market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the alcohol use disorder market in the 7MM.

However, several factors may impede the growth of the alcohol use disorder market. The most common treatments for AUD aim to achieve abstinence and typically include psychological and social interventions. However, underdiagnosis and under-treatment remain prevalent due to factors such as stigma, gender barriers, and others. 

The development of new treatment protocols for AUD is further complicated by challenges in accurately measuring alcohol consumption patterns in patients and the numerous end-organ comorbidities associated with excessive alcohol use. Additionally, country-specific epidemiologic data on diagnosis, severity, and treatment are limited due to changes in AUD diagnostic criteria from DSM-IV to DSM-V.

Moreover, alcohol use disorder treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the alcohol use disorder market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the alcohol use disorder market growth.

To know more about alcohol use disorder companies and drugs, visit @ Alcohol Use Disorder Drugs Market

Scope of the Alcohol Use Disorder Market Report

• Study Period: 2020–2034
• Alcohol Use Disorder Report Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Alcohol Use Disorder Market Size in 2023: USD 620 Million
• Key Alcohol Use Disorder Companies: Adial Pharmaceuticals, Corcept Therapeutics, Clearmind Medicines, Clairvoyant Therapeutics, Alkermes, Lundbeck, Otsuka Pharmaceuticals, and others
• Key Alcohol Use Disorder Therapies: AD04 (ondansetron), CORT 118335 (Miricorilant) (mifepristone), CMND-100, Psilocybin, BP1.3656, VIVITROL, SELINCRO, and others
• Alcohol Use Disorder Therapeutic Assessment: Alcohol Use Disorder current marketed and emerging therapies
• Alcohol Use Disorder Market Dynamics: Conjoint Analysis of Emerging Alcohol Use Disorder Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Alcohol Use Disorder Market Access and Reimbursement

Table of Contents

1. Alcohol Use Disorder Market Key Insights

2. Alcohol Use Disorder Market Report Introduction

3. Alcohol Use Disorder Market Overview at a Glance

4. Alcohol Use Disorder Market Executive Summary

5. Disease Background and Overview

6. Alcohol Use Disorder Treatment and Management

7. Alcohol Use Disorder Epidemiology and Patient Population

8. Patient Journey

9. Alcohol Use Disorder Marketed Drugs

10. Alcohol Use Disorder Emerging Drugs

11. Seven Major Alcohol Use Disorder Market Analysis

12. Alcohol Use Disorder Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/regulatory-analysis-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alcohol Use Disorder Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight

“Liver Fibrosis Treatment Market”

(Albany, USA) DelveInsight’s “Liver Fibrosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Liver Fibrosis, offering comprehensive insights into the Liver Fibrosis revenue trends, prevalence, and treatment landscape. The report delves into key Liver Fibrosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Liver Fibrosis therapies. Additionally, we cover the landscape of Liver Fibrosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Liver Fibrosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Liver Fibrosis space.

To Know in detail about the Liver Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Fibrosis Market Forecast

Some of the key facts of the Liver Fibrosis Market Report: 

• The Liver Fibrosis market size was valued ~USD 2,308 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, the United States represented the largest portion of the Liver Fibrosis market, comprising around 79% of the total market size across the 7MM, surpassing other key regions such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2023, Germany led the EU countries with the highest Liver Fibrosis market size, reaching approximately USD 99 million, while Spain had the smallest market size at around USD 59 million.
• In 2023, supportive therapies in Japan represented a market size of approximately USD 113 million.
• The anticipated introduction of new therapies, including Efruxifermin (AKR-001), Lanifibranor, and Aramchol, is expected to significantly impact the liver fibrosis market size in the coming years.
• Key Liver Fibrosis Companies: Beijing Continent Pharmaceutical, Gilead Sciences, Galmed R&D, Hepion Pharmaceuticals, HK inno.N Corporation, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, InterMune, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Akero Therapeutics, Inc, Pfizer, AstraZeneca, and others
• Key Liver Fibrosis Therapies: Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, oltipraz, IDN-6556, ZED1227, interferon gamma-1b, BMS-986263, peginterferon alfa-2b (SCH 54031), Efruxifermin, PF-06865571, Zibotentan + dapagliflozin, and others
• The Liver Fibrosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Fibrosis pipeline products will significantly revolutionize the Liver Fibrosis market dynamics.
• According to DelveInsight’s assessment, the estimated total number of diagnosed prevalent cases of liver fibrosis in the 7MM was approximately 19 million in 2023.
• In 2023, the United States recorded the highest number of diagnosed prevalent cases of liver fibrosis, with 9 million cases, and this figure is expected to increase in the future.
• In 2023, Germany had the highest number of diagnosed prevalent cases of liver fibrosis among European countries, followed by Italy, while Spain had the fewest cases.
• In 2023, Japan had around 2 million diagnosed prevalent cases of liver fibrosis, representing approximately 12% of the total cases in the 7MM.
• In the US, individuals in the F1 stage of NASH were most impacted by liver fibrosis, with approximately 3 million cases reported in 2023, based on severity-specific diagnosed prevalent cases.
• In 2023, the total diagnosed prevalent cases of NASH-related liver fibrosis in the EU4 and the UK were approximately 1 million.

Liver Fibrosis Overview

Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, in the liver as a result of chronic liver injury. It is a progressive condition that represents a response to liver damage caused by factors such as viral hepatitis (HBV or HCV), alcohol abuse, non-alcoholic fatty liver disease (NAFLD), autoimmune disorders, or exposure to toxins and certain medications.

Fibrosis occurs when repeated injury and inflammation trigger the activation of hepatic stellate cells, which produce fibrous scar tissue. Over time, the buildup of this scar tissue disrupts the liver’s architecture and impairs its ability to function, potentially progressing to cirrhosis, liver failure, or hepatocellular carcinoma.

In its early stages, liver fibrosis is often asymptomatic. As it advances, symptoms such as fatigue, abdominal discomfort, and signs of portal hypertension (e.g., varices, ascites) may develop.

Diagnosis typically involves blood tests, imaging techniques like elastography, and liver biopsy to assess fibrosis severity. The stage of fibrosis is graded on a scale, with advanced stages indicating cirrhosis.

Management focuses on treating the underlying cause, such as antiviral therapy for hepatitis or lifestyle changes for NAFLD. Emerging antifibrotic therapies are being explored, but early intervention remains critical to prevent irreversible liver damage.

Get a Free sample for the Liver Fibrosis Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/liver-fibrosis-market

Liver Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Liver Fibrosis Epidemiology Segmentation:

The Liver Fibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Liver Fibrosis
• Prevalent Cases of Liver Fibrosis by severity
• Gender-specific Prevalence of Liver Fibrosis
• Diagnosed Cases of Episodic and Chronic Liver Fibrosis

Download the report to understand which factors are driving Liver Fibrosis epidemiology trends @ Liver Fibrosis Epidemiology Forecast

Liver Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Fibrosis market or expected to get launched during the study period. The analysis covers Liver Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on

market share.

The report also covers the Liver Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Liver Fibrosis Therapies and Key Companies

• Hydronidone capsules: Beijing Continent Pharmaceutical
• Simtuzumab: Gilead Sciences
• Aramchol: Galmed R&D
• Rencofilstat: Hepion Pharmaceuticals
• oltipraz: HK inno.N Corporation
• IDN-6556: Conatus Pharmaceuticals
• ZED1227: Dr. Falk Pharma GmbH
• interferon gamma-1b: InterMune
• BMS-986263: Bristol-Myers Squibb
• peginterferon alfa-2b (SCH 54031): Merck Sharp & Dohme LLC
• Efruxifermin: Akero Therapeutics, Inc
• PF-06865571: Pfizer
• Zibotentan + dapagliflozin: AstraZeneca

Discover more about therapies set to grab major Liver Fibrosis market share @ Liver Fibrosis Treatment Landscape

Liver Fibrosis Market Drivers

• Rising Prevalence of Chronic Liver Diseases
• Advancements in Diagnostic Techniques
• Ongoing Drug Development
• Awareness Programs
• Government Initiatives

Liver Fibrosis Market Barriers

• High Treatment Costs
• Lack of Approved Therapies
• Slow Diagnosis in Early Stages
• Regulatory Challenges
• Patient Adherence Issues

Scope of the Liver Fibrosis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Liver Fibrosis Companies: Beijing Continent Pharmaceutical, Gilead Sciences, Galmed R&D, Hepion Pharmaceuticals, HK inno.N Corporation, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, InterMune, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Akero Therapeutics, Inc, Pfizer, AstraZeneca, and others
• Key Liver Fibrosis Therapies: Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, oltipraz, IDN-6556, ZED1227, interferon gamma-1b, BMS-986263, peginterferon alfa-2b (SCH 54031), Efruxifermin, PF-06865571, Zibotentan + dapagliflozin, and others
• Liver Fibrosis Therapeutic Assessment: Liver Fibrosis current marketed and Liver Fibrosis emerging therapies
• Liver Fibrosis Market Dynamics: Liver Fibrosis market drivers and Liver Fibrosis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Liver Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Liver Fibrosis Market Access and Reimbursement 

To know more about Liver Fibrosis companies working in the treatment market, visit @ Liver Fibrosis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Liver Fibrosis Market Report Introduction

2. Executive Summary for Liver Fibrosis

3. SWOT analysis of Liver Fibrosis

4. Liver Fibrosis Patient Share (%) Overview at a Glance

5. Liver Fibrosis Market Overview at a Glance

6. Liver Fibrosis Disease Background and Overview

7. Liver Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Fibrosis 

9. Liver Fibrosis Current Treatment and Medical Practices

10. Liver Fibrosis Unmet Needs

11. Liver Fibrosis Emerging Therapies

12. Liver Fibrosis Market Outlook

13. Country-Wise Liver Fibrosis Market Analysis (2020–2034)

14. Liver Fibrosis Market Access and Reimbursement of Therapies

15. Liver Fibrosis Market Drivers

16. Liver Fibrosis Market Barriers

17.  Liver Fibrosis Appendix

18. Liver Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Liver Fibrosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight

“Chronic Pain Associated With Painful Diabetic Neuropathy Treatment Market”

(Albany, USA) DelveInsight’s “Chronic Pain Associated With Painful Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Pain Associated With Painful Diabetic Neuropathy, historical and forecasted epidemiology as well as the Chronic Pain Associated With Painful Diabetic Neuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Pain Associated With Painful Diabetic Neuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Pain Associated With Painful Diabetic Neuropathy Market Forecast

Some of the key facts of the Chronic Pain Associated With Painful Diabetic Neuropathy Market Report:

• The Chronic Pain Associated With Painful Diabetic Neuropathy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Diabetic neuropathy presents a widespread challenge, impacting roughly half of individuals diagnosed with diabetes globally. The occurrence of Painful Diabetic Neuropathy (PDN) escalates to about 50% in cases where diabetes persists for over 25 years, correlating with extended disease duration and inadequate blood sugar management. Approximately 25-30% of diabetic patients may experience distressing neuropathic pain due to PDN, emphasizing the significant burden it imposes on affected individuals.
• As per the National Health Service, around 21–25% of individuals diagnosed with diabetes in the United Kingdom are estimated to experience painful diabetic neuropathy.
• According to the American Diabetes Association, in 2015, diabetes affected 9.4% of the US population, totaling approximately 30.3 million individuals. Around one in six diabetic individuals experience long-standing peripheral neuropathic pain associated with peripheral neuropathy.
• Key Chronic Pain Associated With Painful Diabetic Neuropathy Companies: AstraZeneca, Regenacy Pharmaceuticals, Nevro Corp., Erchonia Corporation, and others
• Key Chronic Pain Associated With Painful Diabetic Neuropathy Therapies: MEDI7352, Ricolinostat, SCS HF10 Technology, Erchonia® EVRL™, and others
• The Chronic Pain Associated With Painful Diabetic Neuropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Pain Associated With Painful Diabetic Neuropathy pipeline products will significantly revolutionize the Chronic Pain Associated With Painful Diabetic Neuropathy market dynamics.

Chronic Pain Associated With Painful Diabetic Neuropathy Overview

Chronic pain associated with painful diabetic neuropathy (PDN) is a debilitating condition resulting from nerve damage caused by prolonged high blood sugar levels in individuals with diabetes. This condition primarily affects the peripheral nerves, leading to persistent pain that can significantly impair quality of life.

The hallmark symptoms include burning, stabbing, or shooting pain, often described as electric shocks, tingling, or numbness. The pain typically begins in the feet and legs and may worsen at night. In severe cases, it can extend to the hands and arms, accompanied by hypersensitivity to touch or temperature changes.

The underlying cause is the metabolic and vascular damage inflicted on nerves by chronic hyperglycemia, oxidative stress, and inflammation. Risk factors include poorly managed diabetes, a long duration of the disease, obesity, smoking, and a sedentary lifestyle.

Treatment focuses on managing blood sugar levels and alleviating pain. First-line therapies include medications such as anticonvulsants (e.g., gabapentin, pregabalin) and antidepressants (e.g., duloxetine, amitriptyline). Additional options include topical agents, physical therapy, and non-pharmacological interventions like cognitive-behavioral therapy.

Preventive strategies involve tight glycemic control, a balanced diet, regular exercise, and routine foot care to reduce the risk of nerve damage and improve overall well-being.

Get a Free sample for the Chronic Pain Associated With Painful Diabetic Neuropathy Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/chronic-pain-associated-with-painful-diabetic-neuropathy-market

Chronic Pain Associated With Painful Diabetic Neuropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Pain Associated With Painful Diabetic Neuropathy Epidemiology Segmentation:

The Chronic Pain Associated With Painful Diabetic Neuropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Chronic Pain Associated With Painful Diabetic Neuropathy
• Prevalent Cases of Chronic Pain Associated With Painful Diabetic Neuropathy by severity
• Gender-specific Prevalence of Chronic Pain Associated With Painful Diabetic Neuropathy
• Diagnosed Cases of Episodic and Chronic Chronic Pain Associated With Painful Diabetic Neuropathy

Download the report to understand which factors are driving Chronic Pain Associated With Painful Diabetic Neuropathy epidemiology trends @ Chronic Pain Associated With Painful Diabetic Neuropathy Epidemiology Forecast

Chronic Pain Associated With Painful Diabetic Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pain Associated With Painful Diabetic Neuropathy market or expected to get launched during the study period. The analysis covers Chronic Pain Associated With Painful Diabetic Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Pain Associated With Painful Diabetic Neuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Pain Associated With Painful Diabetic Neuropathy Therapies and Key Companies

• MEDI7352: AstraZeneca
• Ricolinostat: Regenacy Pharmaceuticals
• SCS HF10 Technology: Nevro Corp.
• Erchonia® EVRL™: Erchonia Corporation

Click here to know more about Chronic Pain Associated With Painful Diabetic Neuropathy therapeutics market @ Chronic Pain Associated With Painful Diabetic Neuropathy Medication

Scope of the Chronic Pain Associated With Painful Diabetic Neuropathy Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Pain Associated With Painful Diabetic Neuropathy Companies: AstraZeneca, Regenacy Pharmaceuticals, Nevro Corp., Erchonia Corporation, and others
• Key Chronic Pain Associated With Painful Diabetic Neuropathy Therapies: MEDI7352, Ricolinostat, SCS HF10 Technology, Erchonia® EVRL™, and others
• Chronic Pain Associated With Painful Diabetic Neuropathy Therapeutic Assessment: Chronic Pain Associated With Painful Diabetic Neuropathy current marketed and Chronic Pain Associated With Painful Diabetic Neuropathy emerging therapies
• Chronic Pain Associated With Painful Diabetic Neuropathy Market Dynamics: Chronic Pain Associated With Painful Diabetic Neuropathy market drivers and Chronic Pain Associated With Painful Diabetic Neuropathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chronic Pain Associated With Painful Diabetic Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Associated With Painful Diabetic Neuropathy Market Access and Reimbursement

To know more about Chronic Pain Associated With Painful Diabetic Neuropathy companies working in the treatment market, visit @ Chronic Pain Associated With Painful Diabetic Neuropathy Treatment Market

Table of Contents

1. Chronic Pain Associated With Painful Diabetic Neuropathy Market Report Introduction

2. Executive Summary for Chronic Pain Associated With Painful Diabetic Neuropathy

3. SWOT analysis of Chronic Pain Associated With Painful Diabetic Neuropathy

4. Chronic Pain Associated With Painful Diabetic Neuropathy Patient Share (%) Overview at a Glance

5. Chronic Pain Associated With Painful Diabetic Neuropathy Market Overview at a Glance

6. Chronic Pain Associated With Painful Diabetic Neuropathy Disease Background and Overview

7. Chronic Pain Associated With Painful Diabetic Neuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Pain Associated With Painful Diabetic Neuropathy

9. Chronic Pain Associated With Painful Diabetic Neuropathy Current Treatment and Medical Practices

10. Chronic Pain Associated With Painful Diabetic Neuropathy Unmet Needs

11. Chronic Pain Associated With Painful Diabetic Neuropathy Emerging Therapies

12. Chronic Pain Associated With Painful Diabetic Neuropathy Market Outlook

13. Country-Wise Chronic Pain Associated With Painful Diabetic Neuropathy Market Analysis (2019-2032)

14. Chronic Pain Associated With Painful Diabetic Neuropathy Market Access and Reimbursement of Therapies

15. Chronic Pain Associated With Painful Diabetic Neuropathy Market Drivers

16. Chronic Pain Associated With Painful Diabetic Neuropathy Market Barriers

17. Chronic Pain Associated With Painful Diabetic Neuropathy Appendix

18. Chronic Pain Associated With Painful Diabetic Neuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/regulatory-analysis-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Pain Associated With Painful Diabetic Neuropathy Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight